Akynzeo and Mucosal inflammation - a phase IV clinical study of FDA data

Summary:

Mucosal inflammation is reported as a side effect among people who take Akynzeo (netupitant; palonosetron hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Oxycodone, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Mucosal inflammation when taking Akynzeo. It is created by eHealthMe based on reports of 1,331 people who have side effects when taking Akynzeo from the FDA, and is updated regularly.

What is Akynzeo?

Akynzeo has active ingredients of netupitant; palonosetron hydrochloride. eHealthMe is studying from 1,332 Akynzeo users. Check the latest studies of Akynzeo.

What is Mucosal inflammation?

Mucosal inflammation (infection of mucous membrane) is found to be associated with 1,191 drugs and 1,239 conditions by eHealthMe. Check the latest studies of Mucosal inflammation.

On Jul, 22, 2026

1,331 people reported to have side effects when taking Akynzeo.
Among them, 17 people (1.28%) have Mucosal inflammation.

Could Akynzeo cause Mucosal inflammation?

Among these 17 people:

How long have people been on Akynzeo when they have Mucosal inflammation? *

What is the gender of people who have Mucosal inflammation when taking Akynzeo? *

female: 47.06 %
male: 52.94 %

What is the age of people who have Mucosal inflammation when taking Akynzeo? *

What are other drugs people take besides Akynzeo? *

What are other side effects people have besides Mucosal inflammation? *

Erythema Multiforme (a type of hypersensitivity reaction): 7 people, 41.18%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 41.18%
Heart Disease: 6 people, 35.29%
Arrhythmias (irregular heartbeat): 6 people, 35.29%
Bone Pain: 6 people, 35.29%
Dyspnea (difficult or laboured breathing): 6 people, 35.29%
Weakness: 6 people, 35.29%
Fatigue (feeling of tiredness): 6 people, 35.29%
Fluid Intake Reduced: 6 people, 35.29%
Weight Decreased: 6 people, 35.29%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 7 people, 41.18%
Breast Cancer: 6 people, 35.29%
Taste - Impaired: 1 person, 5.88%
Small Cell Lung Cancer Extensive Stage (small cell lung cancer that has spread (metastasized) to other regions of the body such as another lobe of the lung or the brain): 1 person, 5.88%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 1 person, 5.88%
Oesophageal Adenocarcinoma (a cancer tumour of an epithelium in oesophagus): 1 person, 5.88%
Lung Cancer Metastatic (lung cancer spreads to other parts): 1 person, 5.88%
Lacrimation Increased: 1 person, 5.88%
Constipation: 1 person, 5.88%
Back Pain: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Akynzeo and have Mucosal inflammation?

- Check whether Mucosal inflammation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Akynzeo:

Akynzeo (1,332 reports)

Mucosal inflammation treatments and more:

Mucosal inflammation (31,547 reports)

How severe was Mucosal inflammation and when was it recovered:

Mucosal inflammation in Akynzeo

Expand to all the drugs that have ingredients of netupitant; palonosetron hydrochloride:

Mucosal inflammation and drugs with ingredients of netupitant; palonosetron hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Akynzeo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mucosal inflammation:

Mucosal inflammation (1,191 drugs)

Browse all the conditions that are associated with Mucosal inflammation:

Mucosal inflammation (1,239 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on netupitant; palonosetron hydrochloride (the active ingredients of Akynzeo) and Akynzeo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.